Candel Therapeutics Inc. has released a corporate presentation detailing progress across its clinical pipeline and financial standing. The company highlighted positive results for its lead product candidate, CAN-2409, including data from a phase 3 randomized placebo-controlled clinical trial in localized, intermediate-to-high-risk prostate cancer, as well as positive overall survival data from randomized phase 2a trials in borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. CAN-2409 has received multiple FDA designations, including Fast Track in several indications and Regenerative Medicine Advanced Therapy (RMAT) in prostate cancer. Candel's second candidate, CAN-3110, is being developed for recurrent high-grade glioma and has shown proof of concept in clinical studies. As of September 30, 2025, the company reported cash and cash equivalents of $87.2 million, with pre-commercialization activities for CAN-2409 underway. You can access the full presentation through the link below.